12:00 AM
 | 
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ReN001: Phase I ongoing

ReNeuron said an independent DSMB recommended continuation to the fourth and final cohort in the open-label, dose-escalation, U.K. Phase I PISCES trial of intracranial ReN001 after reviewing 3-month, follow-up data from the third cohort. PISCES is evaluating 2 million, 5 million, 10 million or...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >